Dermata Therapeutics, Inc. (NASDAQ: DRMA)
Company Profile — For Informational & Educational Use Only
Overview
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing topical dermatology treatments using its proprietary Spongilla Technology platform. The company aims to create cost-effective therapies that enhance drug delivery into the skin for conditions such as acne, rosacea, and hyperhidrosis.
Headquarters: San Diego, California
Sector: Biotechnology
Exchange: NASDAQ Capital Market
Share Structure
(Figures should be verified using the latest SEC filings)
Public Float: ~under 1 million shares
Shares Outstanding: Refer to most recent 10-Q/10-K
Authorized Shares: Refer to SEC filings
Market Capitalization: Micro-cap range (varies by day)
Insider/Institutional Ownership: As reported in the latest DEF 14A and 13F filings
Dermata is characterized by an unusually low public float for a NASDAQ-listed issuer, which may contribute to elevated price volatility.
Business Summary
Dermata is developing new dermatology therapeutics using its Spongilla-derived delivery technology.
Key programs include:
DMT310 – A once-weekly topical acne treatment candidate
DMT410 – A combination therapy platform being explored for hyperhidrosis and aesthetic applications
The company’s goal is to improve efficacy and reduce irritation compared to traditional topical dermatology treatments.
Recent Filings & Financial Position
Dermata is a pre-commercial clinical-stage biotech company. Its SEC filings typically reflect:
Research and development expense as the largest cost component
Limited or no revenue
Dependence on external financing
Expected ongoing capital requirements to support clinical operations
Investors should review the most recent 10-K, 10-Q, and 8-K filings for complete details on operating results, cash position, and corporate activities.
Recent News & Activity
Recent updates may include:
Clinical trial progress
Intellectual property announcements
Study results or data presentations
Financing or capital structure updates
Corporate developments
A full timeline should be reviewed through official press releases and SEC filings.
Potential Catalysts (For informational purposes only)
Biotechnology microcaps may experience changes in market attention following:
Top-line clinical trial results
FDA-related submissions
Conference presentations
Partnership announcements
Funding or restructuring updates
Catalyst timing and impact vary significantly and should be reviewed directly from company disclosures.
Risk Considerations
Dermata operates in a high-risk sector with factors that may include:
Early-stage clinical programs
Need for ongoing capital raises
Uncertain regulatory outcomes
Potential dilution
Volatile trading behavior typical of low-float microcaps
Competitive pressures within the dermatology sector
All risks should be evaluated through the company’s official filings.
Summary
Dermata Therapeutics is a NASDAQ-listed micro-cap biotechnology company focused on dermatology treatments using proprietary topical delivery technology. Its unique share structure, early-stage pipeline, and clinical development efforts are fully described in its public disclosures. This profile is presented solely for informational and educational purposes and does not constitute investment advice.